Gracy Zacharian

440 total citations
5 papers, 343 citations indexed

About

Gracy Zacharian is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Gracy Zacharian has authored 5 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 2 papers in Pathology and Forensic Medicine and 2 papers in Immunology. Recurrent topics in Gracy Zacharian's work include Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (2 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Gracy Zacharian is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (2 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Gracy Zacharian collaborates with scholars based in United States and Germany. Gracy Zacharian's co-authors include Michael J. Keating, Xuelin Huang, Jan A. Burger, Julia Hoellenriegel, William G. Wierda, Alessandra Ferrajoli, Hagop M. Kantarjian, Susan Lerner, Marylou Cárdenas-Turanzas and Ghayathri Jeyakumar and has published in prestigious journals such as Blood and The Lancet Oncology.

In The Last Decade

Gracy Zacharian

5 papers receiving 339 citations

Peers

Countries citing papers authored by Gracy Zacharian

Since Specialization

Citations

This map shows the geographic impact of Gracy Zacharian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gracy Zacharian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gracy Zacharian more than expected).

Fields of papers citing papers by Gracy Zacharian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gracy Zacharian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gracy Zacharian. The network helps show where Gracy Zacharian may publish in the future.

Co-authorship network of co-authors of Gracy Zacharian

This figure shows the co-authorship network connecting the top 25 collaborators of Gracy Zacharian. A scholar is included among the top collaborators of Gracy Zacharian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gracy Zacharian. Gracy Zacharian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study 2014 ·The Lancet Oncology ·Jan A. Burger, Michael J. Keating, William G. Wierda, Elena Hartmann, Julia Hoellenriegel, Nathalie Y. Rosin, Iris de Weerdt, Ghayathri Jeyakumar, Alessandra Ferrajoli, Marylou Cárdenas-Turanzas, Susan Lerner, Jeffrey L. Jorgensen, Graciela M. Nogueras‐González, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, Naveen Garg, Andreas Rosenwald, Susan O’Brien	260
2	Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia 2014 ·Blood ·Ekaterina Kim, Lillian Werner, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Zeev Estrov, Gracy Zacharian, Thomas J. Kipps, Hagop M. Kantarjian, Donna Neuberg, Susan O’Brien, Jan A. Burger	1
3	Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients 2013 ·Blood ·Jan A. Burger, Michael J. Keating, William G. Wierda, Julia Hoellenriegel, Ghayathri Jeyakumar, Alessandra Ferrajoli, Stefan Faderl, Marylou Cárdenas-Turanzas, Susan Lerner, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, Susan O’Brien	36
4	The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients 2012 ·Blood ·Jan A. Burger, Michael J. Keating, William G. Wierda, Julia Hoellenriegel, Alessandra Ferrajoli, Stefan Faderl, Susan Lerner, Gracy Zacharian, Xuelin Huang, Danelle F. James, Joseph J. Buggy, Hagop M. Kantarjian, Susan O’Brien	42
5	Phase I Study of Continuous-Infusion Nelarabine in Patients with Advanced Lymphoid Malignancies 2011 ·Blood ·Tapan M. Kadia, Varsha Gandhi, Deborah A. Thomas, Farhad Ravandi, William Plunkett, Mary Ayres, Yuling Chen, Gracy Zacharian, Gautam Borthakur, Hagop M. Kantarjian, Michael J. Keating	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact